Pure drug nanoparticles in tablets: What are the dissolution limitations?

Journal of Nanoparticle Research

Volumn 12, Issue 5, 2010, Pages 1743-1754

  Heng, Desmond ^a,d,e   Ogawa, Keiko ^b   Cutler, David J ^a   Chan, Hak Kim ^a   Raper, Judy A ^c   Ye, Lin ^a   Yun, Jimmy ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NITTO DENKO CORPORATION   (Japan)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d NanoMaterials Technology Pte Ltd   (Singapore)

^e INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

Author keywords

Cefuroxime axetil; Drug nanoparticles; Nanomedicine; Poorly water soluble drug; Solid dosage form; Taguchi

Indexed keywords

DRUG NANOPARTICLES; NANOMEDICINES; POORLY WATER-SOLUBLE DRUGS; SOLID DOSAGE FORMS; TAGUCHI;

AGGLOMERATION; DISSOLUTION; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; SODIUM; SURFACE ACTIVE AGENTS; TENSILE STRENGTH;

DRUG DOSAGE;

BICARBONATE; CEFUROXIME AXETIL; CITRIC ACID; CROSCARMELLOSE SODIUM; DILUENT; DODECYL SULFATE SODIUM; EXCIPIENT; HYDROXYPROPYLMETHYLCELLULOSE; MANNITOL; MICROCRYSTALLINE CELLULOSE; NANOPARTICLE; PEARLITOL; UNCLASSIFIED DRUG; VIVAPUR 102;

ARTICLE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; ENERGY TRANSFER; NANOMEDICINE; PARTICLE SIZE; PRIORITY JOURNAL; TABLET; TENSILE STRENGTH;

EID: 77955086347     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-009-9759-y     Document Type: Article

References (54)

1. Adams DH, Wood MJ, Farrell ID (1985) Oral cefuroxime axetil: clinical pharmacology and comparative dose studies in urinary tract infection. J Antimicrob Chemother 16:359-366
2. Aguiar AJ, Zelmer JE, Kinkel AW (1967) Deaggregation behavior of a relatively insoluble substituted benzoic acid and its sodium salt. J Pharm Sci 56(10):1243-1252
3. Alderborn G (2005) Tablets and compaction. In: Aulton ME (ed) Pharmaceutics. The science of dosage form design, 2nd edn. Elsevier, London, pp 397-440
4. Ashford M (2005) Bioavailability-physicochemical and dosage form factors. In: Aulton ME (ed) Pharmaceutics. The science of dosage form design, 2nd edn. Elsevier, London, pp 234-252
5. Attwood D, Florence AT (1983) Surfactant systems, their chemistry, pharmacy and biology. Chapman & Hall, New York
6. Brown CK, Chokshi HP, Nickerson B, Reed RA, Rohrs BR, Shah PA (2004) Acceptable analytical practices for dissolution testing of poorly soluble compounds. Pharm Technol 28: 56-65
7. Busignies V, Leclerc B, Porion P, Evesque P, Couarraze G, Tchoreloff P (2006) Compaction behaviour and new predictive approach to the compressibility of binary mixtures of pharmaceutical excipients. Eur J Pharm Biopharm 64:66-74
8. Chen JF, Zhang JY, Shen ZG, Zhong J, Yun J (2006) Preparation and characterisation of amorphous cefuroxime axetil drug nanoparticles with novel technology: highgravity antisolvent precipitation. Ind Eng Chem Res 45(25):8723-8727
9. Date AA, Patravale VB (2004) Current strategies for engineering drug nanoparticles. Curr Opin Colloid Interface Sci 9:222-235
10. David ST, Augsburger LL (1974) Flexure test for determination of tablet tensile strength. J Pharm Sci 63:933-936
11. Diemunsch AM, Pabst JY, Constant C, Mathis C, Stamm A (1993) Tablet formulation: Genichi Taguchi's approach. Drug Dev Ind Pharm 19(12):1461-1477
12. Dokoumetzidis A, Macheras P (2006) A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 321:1-11
13. Dressman JB, Amidon GL, Reppas C, Shah VP (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15(1):11-22
14. Edge S, Steele DF, Chen A, Tobyn MJ, Staniforth JN (2000) The mechanical properties of compact of microcrystalline cellulose and silicified microcrystalline cellulose. Int J Pharm 200:67-72
15. Edge S, Steele DF, Tobyn MJ, Staniforth JN, Chen A (2001) Directional bonding in compacted microcrystalline cellulose. Drug Dev Ind Pharm 27(7):613-621
16. Eerikainen H, Watanabe W, Kauppinen EI, Ahonen PP (2003) Aerosol flow reactor method for synthesis of drug nanoparticles. Eur J Pharm Biopharm 55:357-360
17. El-Shabouri MH (2002) Nanoparticles for improving the dissolution and oral bioavailability of spironolactone, a poorly-soluble drug. STP Pharm Sci 12(2):97-101
18. Esezobo S, Pilpel N (1977) Formulation factors affecting strength and dissolution of uncoated oxytetracycline tablets. J Pharm Sci 66(6):852-858
19. Fassihi AR (1986) Mechanisms of disintegration and compactibility of disintegrants in a direct compression system. Int J Pharm 32:93-96
20. Fell JT, Newton JM (1970) Determination of tablet strength by the diametral-compression test. J Pharm Sci 59(5):688-691
21. Florence AT (2007) Pharmaceutical nanotechnology: more than size. Ten topics for research. Int J Pharm 339:1-2
22. Gupta RB (2006) Fundamentals of drug nanoparticles. In: Gupta RB, Kompella UB (eds) Drugs and the pharmaceutical sciences: nanoparticle technology for drug delivery. Taylor & Francis, London, pp 6-9
23. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA (2008a) Dissolution kinetic behavior of drug nanoparticles and their conformity to the diffusion model. Langmuir 24(14): 7538-7544
24. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA (2008b) What is a suitable dissolution method for drug nanoparticles? Pharm Res 25(7):1696-1701
25. Huang J, Bartell LS (2001) Structure and properties of potassium iodide nanoparticles. A molecular dynamics study. J Mol Struct 567-568:145-156
26. Iskandarani B, Clair JH, Patel P, Shiromani PK, Dempski RE (1993) Simultaneous optimization of capsule and tablet formulation using response surface methodology. Drug Dev Ind Pharm 19(16):2089-2101
27. Johnson BK, Prud'homme RK (2003) Chemical processing and micromixing in confined impinging jets. AlChE Journal 49(9):2264-2282
28. Jose-Yacaman M, Gutierrez-Wing C, Miki M, Yang DQ, Piyakis KN, Sacher E (2005) Surface diffusion and coalescence of mobile metal nanoparticles. J Phys Chem B 109:9703-9711
29. Kanfer I (2002) Report on the international workshop on the biopharmaceutics classification system (BCS): scientificand regulatory aspects in practice. J Pharm Pharm Sci 5(1):1-4
30. Katz LM (2007) Nanotechnology and applications in cosmetics: general overview. Am Chem Soc Symp Ser 961: 193-200
31. Kesisoglou F, Panmai S, Wu Y (2007) Application of nanoparticles in oral delivery of immediate release formulations. Curr Nanosci 3:183-190
32. Kim KD, Choi DW, Choa YH, Kim HT (2007) Optimization of parameters for the synthesis of zinc oxide nanoparticles by Taguchi robust design method. Colloids Surf A 311:170-173
33. Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T et al (2005) Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm 31:319-329
34. Larhrib H, Wells JI (1997) Compression of thermally treated polyethylene glycol 10 000. Int J Pharm 153:51-58
35. Lee J (2003) Drug nano and microparticles processed into solid dosage forms: physical properties. J Pharm Sci 92(10): 2057-2068
36. Lee J (2007) Nanoscopic friction behavior of pharmaceutical materials. Int J Pharm 340:191-197
37. Liu J, Stewart PJ (1998) Deaggregation during the dissolution of benzodiazepines in interactive mixtures. J Pharm Sci 87(12):1632-1638
38. Lopez-QuintelaMA(2003) Synthesis of nanomaterials in microemulsions: formation mechanisms and growth control. Current Opin Colloid Interface Sci 8(2):137-144
39. Mackay ME, Dao TT, Tuteja A, Ho DL, van Horn B, Kim H et al (2003) Nanoscale effects leading to non-Einstein-like decrease in viscosity. Nat Mater 2:762-766
40. Muller RH, Junghanns JAH (2006) Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs. In: Torchilin VP (ed) Nanoparticulates as drug carriers. Imperial College Press, London, pp 308-309
41. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB (2006) Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 317:82-89
42. Obae K, Iijima H, Imada K (1999) Morphological effect of microcrystalline cellulose particles on tablet tensile strength. Int J Pharm 182:155-164 (Pubitemid 29248844)
43. Palmieri GF, Wehrle P (1997) Evaluation of ethylcellulosecoated pellets optimized using the approach of Taguchi. Drug Dev Ind Pharm 23(11):1069-1077
44. Peace GS (1993) Taguchi methods. A hands-on approach to quality engineering. Addison-Wesley, Massachusetts Rees JE, Rue PJ (1978) Work required to cause failure of tablets in diametral compression. Drug Dev Ind Phar 4(2):131-156
45. Reverchon E, Adami R (2006) Nanomaterials and supercritical fluids. J Supercrit Fluids 37:1-22
46. Ruddy SB, Matuszewska BK, Grim YA, Ostovic D, Storey DE (1999) Design and characterization of a surfactantenriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. Int J Pharm 182:173-186
47. Ryu JM, Cho SK, Jung SH, Seong SK, Cho EH, Ahn SH et al (2006) An oral preparation having improved bioavailability (WO 2006/057507 A1), Korea
48. Sager TM, Porter DW, Robinson VA, Lindsley WG, Schwegler-Berry DE, Castranova V (2007) Improved method to disperse nanoparticles for in vitro and in vivo investigation of toxicity. Nanotoxicology 1(2):118-129
49. Taguchi G (1986) Introduction to quality engineering: designing quality into products and processes. Kraus International Publications, White Plains, NY
50. Varshosaz J, Hassanzadeh F, Mahmoudzadeh M, Sadeghi A (2009) Preparation of cefuroxime axetil nanoparticles by rapid expansion of supercritical fluid technology. Powder Technol 189:97-102
51. Wang J, Flanagan DR (2002) General solution for diffusioncontrolled dissolution of spherical particles. 2. Evaluation of experimental data. J Pharm Sci 91(2):534-542
52. Yang K, Teo E-C, Fuss FK (2007) Application of Taguchi method in optimization of cervical ring cage. J Biomech 40:3251-3256
53. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ et al (2006) Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 323:153-160
54. Zhao N, Augsburger L (2005) Functionality comparison of 3 classes of superdisintegrants in promoting aspirin tablet disintegration and dissolution. AAPS PharmSciTech 6(4):E634-E640